• Citer

Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.

par Westphal, Manfred;Ylä-Herttuala, Seppo Pasi Antero S.;Martin, John;Warnke, Peter;Menei, Philippe P;Eckland, David D;Kinley, Judith J;Kay, Richard;Ram, Zvi;De Witte, Olivier
Référence Lancet oncology, 14, 9, page (823-833)
Publication Publié, 2013-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Besides the use of temozolomide and radiotherapy for patients with favourable methylation status, little progress has been made in the treatment of adult glioblastoma. Local control of the disease by complete removal increases time to progression and survival. We assessed the efficacy and safety of a locally applied adenovirus-mediated gene therapy with a prodrug converting enzyme (herpes-simplex-virus thymidine kinase; sitimagene ceradenovec) followed by intravenous ganciclovir in patients with newly diagnosed resectable glioblastoma.